Joshua Feder, MD. Dr. Feder has no financial relationships with companies related to this material.
NMS is feared but poorly characterized in pediatric populations. A Medicaid cohort of 1.66 million young antipsychotic users now offers the clearest picture yet of when risk is highest and which combinations clinicians should watch most closely.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
